nach oben

Erschienen in:

01.06.2019 | Case report

Dalbavancin

Skin rash: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In an observational, retrospective study of 64 patients conducted between March 2016 and November 2017, a patient [age and sex not stated] was described, who developed skin rash during treatment with dalbavancin for bone and joint infection. The patient started receiving dalbavancin infusion [dosage not stated]. After the first dose, the patient developed a self-limited skin rash [time to reaction onset not stated]. However, during the subsequent infusions, the rash did not recur. …

Morata L, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrobial Agents and Chemotherapy 63: e02280-18, No. 5, May 2019. Available from: URL: http://doi.org/10.1128/AAC.02280-18 - Spain

Titel: Dalbavancin
Skin rash: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63974-8

Springer Medizin

Dalbavancin

Skin rash: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Influenza virus vaccine

Bevacizumab

Denosumab

Antithrombin-III/thrombomodulin-α

Cefepime overdose

Antineoplastics/bisphosphonates

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Influenza virus vaccine

Bevacizumab

Denosumab

Antithrombin-III/thrombomodulin-α

Cefepime overdose

Antineoplastics/bisphosphonates